Research has linked greater segregation within black communities can lead to higher prevalence of hypertension. A recent study, published online May 15 in JAMA Internal Medicine, examined how changes in exposure to segregation affected high blood pressure.

Australian researchers have announced patients who recently had respiratory infections are 17 times more likely to experience heart attack. The findings, published in the Internal Medicine Journal, could be related to such infections activating blood cells and the body's clotting system.

A new study from Cincinnati’s Children’s Hospital has found that the use of a wearable cardioverter defibrillator (WCD) is safe and effective for treating ventricular arrhythmias in pediatric patients at risk from sudden cardiac death.

Apple devices just keep getting smarter. New research presented at this year’s Heart Rhythm Society (HRS) conference in Chicago showed that when paired with an artificial intelligence-based algorithm, the watch can detect atrial fibrillation (AFib). 

The May 12 late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans compared femoral and radial robotic percutaneous coronary intervention (PCI) procedures.

Though physicians typically use adenosine, calcium channel blockers or beta-blockers in patients suffering from paroxysmal supraventricular tachycardia (PSVT), new research has given evidence that a simple, self-use nasal spray could be effective, too.

NEW ORLEANS and MARLBOROUGH, Mass., May 12, 2017 /PRNewswire/ -- New analyses from the Boston Scientific Corporation (NYSE: BSX) sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can adversely affect stent-related outcomes. Aligned with the Boston Scientific "Close the Gap" health equity initiative, PLATINUM Diversity is a first-of-its-kind study focusing exclusively on women and minorities with coronary artery disease that is designed to shed light into the clinical, social, behavioral and economic determinants of health treatment outcome disparities in these groups.

MARLBOROUGH, Mass., May 12, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a late-breaking clinical trial session at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions in Chicago. Data confirmed that the WATCHMAN device had a high implant success rate and was effective in stroke reduction for patients with non-valvular atrial fibrillation (AF), including those patients deemed unsuitable for oral anticoagulation.